AstraZeneca wins damages from Apotex
Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning said it welcomed the US District Court for the Southern District of New York ruling, which ordered Canadian generic firm Apotex Corp and its subsidiary Torpharm to pay AstraZeneca around $76 million in damages.
This ruling is a result of Apotex’ infringing sales of AstraZeneca’s gastro-intestinal drug omeprazole between 2004 and 2007 with a generic version. This follows a previous ruling in 2007 that found two Prilosec (omeprazole) formulation patents valid and infringed by Apotex.
US District Judge Denise Cote in New York said Apotex must pay AstraZeneca the equivalent of 50% of its profits during the three-and-a-half years it sold a generic version of Prilosec.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze